Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide in Healthy Chinese Adults
NCT07510529Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2026
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deuremidevir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Geometric mean ratios and their 90% confidence intervals for the primary PK parameters at Day 10. Started Apr 2026; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07510529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510529.